Intec and Impax collaborate on CNS drug development

Intec Pharma, the Israel-based developer of the Accordion Pill gastric retention technology, says that it has entered into a collaboration agreement with Impax Laboratories, a US specialty pharmaceutical company in order to develop a central nervous system drug, based on a known compound. Intec will use its proprietary Accordion Pill technology to develop and manufacture the drug while Impax will conduct clinical trials and commercialize the product. The financial terms of the agreement were not disclosed.

Efi Cohen-Arazi, chief executive of Intec, said: "the signing of this agreement is an important step in our two-pronged business strategy aimed at creating a whole new generation of drugs. In addition to developing our own pipeline products we will be licensing out our proprietary technology to strategic partners on a project-by-project basis."